Neurofibromatosis Type 2 (NF2) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
-1.jpg)
Neurofibromatosis type 2 (NF2) is an autosomal-dominant tumor-prone disorder predisposed to nerve system tumors. Bilateral vestibular schwannoma (VS) is pathognomonic or the disease, whereas schwannoma at other locations, meningiomas, ependymomas, and early onset lenticular opacities are frequently associated with the phenotypes. Vestibular schwannoma-related symptoms were seen in most of the patients (55%), followed by ophthalmological symptoms/abnormalities (45%) and cutaneous features (38%). About 40% of all patients were monosymptomatic, 55% showed ≥2 symptoms at symptom onset, and ~5% were asymptomatic. Including polysymptomatic occurrence and symptomatic and asymptomatic findings, 62% of young patients exhibit ophthalmological abnormalities, followed by cutaneous findings (43%). Most people with NF2 develop symptoms in the late teen and early adult years, although about 10% of people develop symptoms during late childhood. The most common symptoms of NF2 include ringing in the ears (tinnitus), gradual hearing loss, and balance problems.
- Neurofibromatosis type 2 (NF2) incidence ranges from 1 to 1.2 cases in 40,000 live births Neurofibromatosis type 2 (NF2).
Thelansis’s “Neurofibromatosis Type 2 (NF2) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neurofibromatosis Type 2 (NF2) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Neurofibromatosis Type 2 (NF2) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Neurofibromatosis Type 2 (NF2) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment